Cargando…

Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies

Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional funct...

Descripción completa

Detalles Bibliográficos
Autores principales: Chasov, Vitaly, Zaripov, Mikhail, Mirgayazova, Regina, Khadiullina, Raniya, Zmievskaya, Ekaterina, Ganeeva, Irina, Valiullina, Aigul, Rizvanov, Albert, Bulatov, Emil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411701/
https://www.ncbi.nlm.nih.gov/pubmed/34484205
http://dx.doi.org/10.3389/fimmu.2021.707734
_version_ 1783747342355136512
author Chasov, Vitaly
Zaripov, Mikhail
Mirgayazova, Regina
Khadiullina, Raniya
Zmievskaya, Ekaterina
Ganeeva, Irina
Valiullina, Aigul
Rizvanov, Albert
Bulatov, Emil
author_facet Chasov, Vitaly
Zaripov, Mikhail
Mirgayazova, Regina
Khadiullina, Raniya
Zmievskaya, Ekaterina
Ganeeva, Irina
Valiullina, Aigul
Rizvanov, Albert
Bulatov, Emil
author_sort Chasov, Vitaly
collection PubMed
description Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional functions caused by mutations in p53 protein leads to deactivation of intrinsic tumor suppressive responses associated with wild-type (WT) p53 and acquisition of new pro-oncogenic properties such as enhanced cell proliferation, metastasis and chemoresistance. Hotspot mutations of p53 are often immunogenic and elicit intratumoral T cell responses to mutant p53 neoantigens, thus suggesting this protein as an attractive candidate for targeted anti-cancer immunotherapies. In this review we discuss the possible use of p53 antigens as molecular targets in immunotherapy, including the application of T cell receptor mimic (TCRm) monoclonal antibodies (mAbs) as a novel powerful approach.
format Online
Article
Text
id pubmed-8411701
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84117012021-09-03 Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies Chasov, Vitaly Zaripov, Mikhail Mirgayazova, Regina Khadiullina, Raniya Zmievskaya, Ekaterina Ganeeva, Irina Valiullina, Aigul Rizvanov, Albert Bulatov, Emil Front Immunol Immunology Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional functions caused by mutations in p53 protein leads to deactivation of intrinsic tumor suppressive responses associated with wild-type (WT) p53 and acquisition of new pro-oncogenic properties such as enhanced cell proliferation, metastasis and chemoresistance. Hotspot mutations of p53 are often immunogenic and elicit intratumoral T cell responses to mutant p53 neoantigens, thus suggesting this protein as an attractive candidate for targeted anti-cancer immunotherapies. In this review we discuss the possible use of p53 antigens as molecular targets in immunotherapy, including the application of T cell receptor mimic (TCRm) monoclonal antibodies (mAbs) as a novel powerful approach. Frontiers Media S.A. 2021-08-13 /pmc/articles/PMC8411701/ /pubmed/34484205 http://dx.doi.org/10.3389/fimmu.2021.707734 Text en Copyright © 2021 Chasov, Zaripov, Mirgayazova, Khadiullina, Zmievskaya, Ganeeva, Valiullina, Rizvanov and Bulatov https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chasov, Vitaly
Zaripov, Mikhail
Mirgayazova, Regina
Khadiullina, Raniya
Zmievskaya, Ekaterina
Ganeeva, Irina
Valiullina, Aigul
Rizvanov, Albert
Bulatov, Emil
Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
title Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
title_full Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
title_fullStr Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
title_full_unstemmed Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
title_short Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
title_sort promising new tools for targeting p53 mutant cancers: humoral and cell-based immunotherapies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411701/
https://www.ncbi.nlm.nih.gov/pubmed/34484205
http://dx.doi.org/10.3389/fimmu.2021.707734
work_keys_str_mv AT chasovvitaly promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies
AT zaripovmikhail promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies
AT mirgayazovaregina promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies
AT khadiullinaraniya promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies
AT zmievskayaekaterina promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies
AT ganeevairina promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies
AT valiullinaaigul promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies
AT rizvanovalbert promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies
AT bulatovemil promisingnewtoolsfortargetingp53mutantcancershumoralandcellbasedimmunotherapies